RhumbLine Advisers’s Cue Biopharma CUE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-6,645
| Closed | -$8.24K | – | 4230 |
|
|
2024
Q2 | $8.24K | Sell |
6,645
-25,952
| -80% | -$32.2K | ﹤0.01% | 4009 |
|
|
2024
Q1 | $61.6K | Buy |
32,597
+847
| +3% | +$1.6K | ﹤0.01% | 3577 |
|
|
2023
Q4 | $83.8K | Buy |
31,750
+340
| +1% | +$898 | ﹤0.01% | 3504 |
|
|
2023
Q3 | $72.2K | Buy |
31,410
+2,018
| +7% | +$4.64K | ﹤0.01% | 3558 |
|
|
2023
Q2 | $107K | Buy |
+29,392
| New | +$107K | ﹤0.01% | 3501 |
|
|
2022
Q2 | – | Sell |
-31,768
| Closed | -$155K | – | 3127 |
|
|
2022
Q1 | $155K | Sell |
31,768
-36
| -0.1% | -$176 | ﹤0.01% | 2812 |
|
|
2021
Q4 | $360K | Sell |
31,804
-610
| -2% | -$6.91K | ﹤0.01% | 2640 |
|
|
2021
Q3 | $472K | Buy |
32,414
+1,400
| +5% | +$20.4K | ﹤0.01% | 2572 |
|
|
2021
Q2 | $361K | Sell |
31,014
-2,078
| -6% | -$24.2K | ﹤0.01% | 2714 |
|
|
2021
Q1 | $404K | Sell |
33,092
-1,841
| -5% | -$22.5K | ﹤0.01% | 2582 |
|
|
2020
Q4 | $437K | Buy |
34,933
+770
| +2% | +$9.63K | ﹤0.01% | 2493 |
|
|
2020
Q3 | $514K | Sell |
34,163
-1,730
| -5% | -$26K | ﹤0.01% | 2280 |
|
|
2020
Q2 | $880K | Buy |
35,893
+11,262
| +46% | +$276K | ﹤0.01% | 2096 |
|
|
2020
Q1 | $350K | Buy |
24,631
+425
| +2% | +$6.04K | ﹤0.01% | 2330 |
|
|
2019
Q4 | $384K | Buy |
24,206
+576
| +2% | +$9.14K | ﹤0.01% | 2485 |
|
|
2019
Q3 | $199K | Buy |
23,630
+225
| +1% | +$1.9K | ﹤0.01% | 2751 |
|
|
2019
Q2 | $210K | Buy |
23,405
+613
| +3% | +$5.5K | ﹤0.01% | 2772 |
|
|
2019
Q1 | $176K | Sell |
22,792
-3
| -0% | -$23 | ﹤0.01% | 2774 |
|
|
2018
Q4 | $107K | Buy |
22,795
+7,724
| +51% | +$36.3K | ﹤0.01% | 2877 |
|
|
2018
Q3 | $136K | Sell |
15,071
-804
| -5% | -$7.26K | ﹤0.01% | 2820 |
|
|
2018
Q2 | $188K | Buy |
+15,875
| New | +$188K | ﹤0.01% | 2750 |
|